ii) H310A, H433A, and Y436A, or
iii) L251D, L314D, and L432D, or
iv) combinations of i) to iii)

in the first Fc-region polypeptide and in the second Fc-region polypeptide.

One aspect as reported herein is a pharmaceutical formulation comprising an antibody as reported herein and optionally a pharmaceutically acceptable carrier.

One aspect as reported herein is the antibody as reported herein for use as a medicament.

One aspect as reported herein is the antibody as reported herein for use in the treatment of an ocular vascular disease.

As reported herein is the use of the antibody as reported herein in the manufacture of a medicament.

In one embodiment the medicament is for the treatment of an ocular vascular disease, preferably for the treatment of macular degeneration.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

I. DEFINITIONS

An "acceptor human framework" for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework "derived from" a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.

6. A pharmaceutical formulation comprising an antibody according to any one of claims 1 to 5 and optionally a pharmaceutically acceptable carrier.

7. The antibody according to any one of claims 1 to 5 for use as a medicament.

8. The antibody according to any one of claims 1 to 5 for use in the treatment of an ocular vascular disease.